2 results
Approved WMORecruiting
• To assess the tolerability and safety of the investigational medicinal product
Approved WMORecruiting
To prove that the RECAP test has the potential of selecting patients who are sensitive to treatment with the PARP inhibitor talazoparib as measured by the PFS rate at 4 months.